Skip to main content

Independent service, not a government website.

Federal grantOpenGrant opportunity

Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)

Department of Health and Human Services, National Institutes of Health

Grant details

Application deadline
Nov 18, 2027
Posted
Nov 20, 2024
Funding opportunity number
RFA-DA-26-034
Grants.gov ID
357250
Funding instrument
Grant
Category of funding
Education, Health
Opportunity category
Discretionary
Award ceiling
$300,000
Award floor
Not stated
Total program funding
$300,000
Expected awards
Not stated
Cost sharing required
No
Assistance Listing (ALN/CFDA)
  • 93.233 — National Center on Sleep Disorders Research
  • 93.279 — Drug Use and Addiction Research Programs
  • 93.837 — Cardiovascular Diseases Research
  • 93.838 — Lung Diseases Research
  • 93.839 — Blood Diseases and Resources Research
  • 93.840 — Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
  • 93.855 — Allergy and Infectious Diseases Research
Archive date
Dec 24, 2027

Who can apply

Businesses are among the eligible applicants listed on Grants.gov.

  • Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
  • Special district governments
  • Public and State controlled institutions of higher education
  • State governments
  • Independent school districts
  • For profit organizations other than small businesses
  • County governments
  • Native American tribal organizations (other than Federally recognized tribal governments)
  • Private institutions of higher education
  • Public housing authorities/Indian housing authorities
  • Others (see text field entitled "Additional Information on Eligibility" for clarification)
  • Native American tribal governments (Federally recognized)
  • Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
  • Small businesses
  • City or township governments

Additional information on eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

This product uses the Grants.gov API but is not endorsed or certified by the U.S. Department of Health and Human Services.

Description

This notice of funding opportunity (NOFO) will support research towards understanding and mitigating the deleterious effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids (e.g., fentanyl, carfentanil, nitazenes) and their combinations (fentanyl and xylazine). This NOFO will also support research on the persistent and/or delayed pathophysiological effects after acute exposure to such agents.

Announcement and documents

Grantor contact

One point of contact is named on the official Grants.gov listing. Sign in to see names, emails and phones here.

As published on the Grants.gov listing. This office in the buyer directory (paid plans and match reports).

Grants: Grants.gov (federal grant opportunities) · last updated Nov 20, 2026, 4:20 PM ET.

This product uses the Grants.gov API but is not endorsed or certified by the U.S. Department of Health and Human Services.

Always confirm details, amendments and deadlines on the official listing. Government Bid Finder is an independent service and is not affiliated with or endorsed by the U.S. government.